<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805257</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#16-18935</org_study_id>
    <nct_id>NCT02805257</nct_id>
  </id_info>
  <brief_title>Ahmed Glaucoma Valve Surgery With Mitomycin-C</brief_title>
  <acronym>AMCT</acronym>
  <official_title>Ahmed Glaucoma Valve Surgery With Mitomycin-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bascom Palmer Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Ophthalmic Center, Sun Yet-san University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed
      valve implantation. Approximately 100 patients will be enrolled, with half receiving the
      Mitomycin-C treatment and the other half receiving placebo treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is a leading cause irreversible blindness worldwide. Glaucoma valve surgeries such
      as Ahmed valve implantation, which are conventional surgeries performed to control
      intraocular pressure in eyes, are sometimes associated with complications due to fibrosis.
      Mitomycin-C is a commonly used antifibrotic agent used in glaucoma surgeries. This study
      will evaluate the effectiveness of Mitomycin-C injections intraoperatively and
      postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure after surgery</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure after surgery</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medications postoperatively</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell count</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell count</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glaucoma</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Secondary Glaucoma</condition>
  <condition>Neovascular Glaucoma</condition>
  <arm_group>
    <arm_group_label>Mitomycin-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced Salt Solution (BSS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C</intervention_name>
    <description>Intraoperative and postoperative injections of mitomycin-c/Mitosol</description>
    <arm_group_label>Mitomycin-C</arm_group_label>
    <other_name>Mitosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Balanced Salt Solution</intervention_name>
    <description>Intraoperative and postoperative injections of BSS</description>
    <arm_group_label>Balanced Salt Solution (BSS)</arm_group_label>
    <other_name>BSS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inadequately controlled glaucoma on maximum tolerated medical therapy with
             intraocular pressure (IOP) greater than or equal to 18 mm Hg. Ahmed Glaucoma Valve
             (AGV) implantation as the planned surgical procedure. For patients in whom 2 eyes are
             eligible for enrollment, only the first eligible eye to be implanted is enrolled.

        Exclusion Criteria:

          -  Unwilling or unable to give consent, unwilling to accept randomization, or unable to
             return for scheduled protocol visits.

          -  Pregnant or nursing women.

          -  Previous cyclodestruction or glaucoma drainage device (GDD) surgery.

          -  Patients with nanophthalmos.

          -  Patients with Sturge-Weber syndrome or other conditions associated with elevated
             episcleral venous pressure.

          -  No light perception vision.

          -  VA &lt;20/200 in non-study eye.

          -  Need for glaucoma surgery combined with other ocular procedures (i.e. cataract
             extraction, penetrating keratoplasty, or retinal surgery) or anticipated need for
             additional ocular surgery.

          -  Previous scleral buckling procedure or silicone oil present. Uveitic glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Han, MD, PhD</last_name>
    <phone>510-508-0940</phone>
    <email>ying.han@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Coh, BS</last_name>
    <phone>650-228-4066</phone>
    <email>paul.coh@ucsf.edu</email>
  </overall_contact_backup>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 16, 2016</lastchanged_date>
  <firstreceived_date>June 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
